4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
4TEEN4 Pharmaceuticals has raised $35.9M in total funding. The most recent round was Series C. The last funding was announced in November 2025.
4TEEN4 Pharmaceuticals's investors include NRW.BANK, FLORA Ventures, Brandenburg Kapital, Therabel, Toucan Health Innovations.
4TEEN4 Pharmaceuticals is headquartered in Hennigsdorf, Germany.
4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
4TEEN4 Pharmaceuticals is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"4TEEN4 Pharmaceuticals — Funding & Investors." VCBacked, November 13, 2025, https://www.vcbacked.co/company/4teen4-pharmaceuticals. Accessed July 31, 2026.
VCBacked. (2025). 4TEEN4 Pharmaceuticals — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/4teen4-pharmaceuticals
{{cite web |title=4TEEN4 Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/4teen4-pharmaceuticals |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated